Zymogen granule protein 16 (ZG16p) is a soluble lectin that binds to both mannose and heparin/ heparan sulfate. It is highly expressed in the human digestive tract and is secreted into the mucus. In this study, we investigated the effect of ZG16p on the proliferation of human colorectal cancer cells. Overexpression of ZG16p in Caco-2 cells decreased cell growth. Recombinant ZG16p markedly inhibited proliferation of Caco-2, LS174T, HCT116 and HCT15 cells. Caco-2 cell growth was not inhibited by two mutated ZG16p proteins, D151A and M5 (K36A, R37A, R53A, R55A and R79A) lacking mannose-and heparin-binding activities, respectively. Immunofluorescent cell staining revealed that ZG16p-D151A maintained its binding to the Caco-2 cell surface, whereas ZG16p-M5 failed to bind to the cells. These results suggest that ZG16p interacts with the cell surface via basic amino acids substituted in ZG16p-M5 and inhibits Caco-2 cell proliferation via Asp151. In addition, growth of patient-derived colorectal tumor organoids in a 3D intestinal stem cell system was suppressed by ZG16p but not by ZG16p-M5. Taken together, our findings indicate that ZG16p inhibits the growth of colorectal cancer cells via its carbohydrate-binding sites in vitro and ex vivo. In this study, a novel pathway in cancer cell growth regulation through cell surface carbohydrate chains is suggested.
Introduction
Zymogen granule protein 16 (ZG16p) is a soluble protein that was identified in the zymogen granules of the rat pancreas (Cronshagen et al. 1994 ). ZG16p, a highly basic protein (pI 9.0) (Kleene et al. 1999; Schmidt et al. 2000) , binds to the luminal surface of the pancreatic zymogen granule membrane through glycosaminoglycans and modulates condensation-sorting (process of selective packing and sorting of pancreatic enzymes to the zymogen granule membrane) (Kleene et al. 1999; Schmidt et al. 2001) . ZG16p is also expressed in humans and is detected in the goblet cells of the intestine, acinar cells of the pancreas, serosanguineous acinar cells of the parotid gland and the serum (Tateno et al. 2012) . Crystal structural analysis has revealed that ZG16p has a β-prism fold structure similar to mannose-binding Jacalin-related lectins (mJRLs) (Kanagawa et al. 2011 ) such as BanLec (Meagher 2005) , Heltuba (Bourne et al. 1999) , and Artocarpin (Pratap et al. 2002) . mJRLs associate with mannose via their GG, recognition and binding loops (GXXXD) (Meagher 2005) . ZG16p also binds to mannose through the GXXXD loop (Tateno et al. 2012; Kanagawa et al. 2014) . Furthermore, Lys and Arg residues on ZG16p are involved in the interaction with sulfated glycosaminoglycans (Kanagawa et al. 2014) . It has been reported that ZG16b/PAUF (pancreatic adenocarcinoma upregulated factor) and WGA16 isolated from boar sperm also have a β-prism fold structure; however, a key mannose-binding residue (Asp151 in ZG16p) is not conserved (Kanagawa et al. 2011; Garénaux et al. 2015) . ZG16p was shown to bind the pathogenic fungi, Candida and Malassezia (Tateno et al. 2012) , and mycobacterial phosphatidylinositol mannosides (Hanashima et al. 2015 ) through Asp151. In recent studies, ZG16p was detected in gastrointestinal mucus and was found to be correlated with MUC2 mucin in mice (Johansson et al. 2008; Rodríguez-Piñeiro et al. 2013) . Furthermore, immunostaining showed that ZG16p is located in both goblet cells and mucus (Rodríguez-Piñeiro et al. 2013 ) and inhibits penetration of gram-positive bacteria into the mucus (Bergström et al. 2016) . These studies suggest that ZG16p is involved in the intestinal immune system through recognition of pathogens or commensal bacteria. On the other hand, downregulation of ZG16p in human colorectal cancer was reported in 2008 (Alves et al. 2008 ). In addition, it was shown that ZG16p is downregulated by miR-196a overexpression, thereby facilitating progression of colorectal cancer (Chen et al. 2016) . However, the relationship between the reduced expression of ZG16p and the pathogenic conditions of colorectal cancer remained unclear.
Several plant lectins have been reported to regulate the growth of colorectal cancer cell lines. Peanut agglutinin lectin binding to the Thomsen-Friedenreich antigen (Galβ1-3GalNAcα) promotes the proliferation of HT29 cells by activating c-Met and MAPK (Singh 2006) . Mulberry leaf lectin binds to galactose and GalNAc, inducing apoptosis of HCT15 cells (Deepa et al. 2012) . In addition, the effects of endogenous galactoside-binding lectins on colorectal cancer cell growth are also reported. Galectin-4 inhibits growth of some colorectal cancer cell lines (Satelli et al. 2011) . Galectin-3 binds to MUC1 protein and enhances HCT116 cell proliferation by inducing phosphorylation of ERK1/2 and Akt (Mori et al. 2015 ). These observations indicate that possible regulation of colorectal cancer progression by the binding of lectins to cell surface carbohydrate chains may take place.
In this study, we investigated the effect of lectin ZG16p on the proliferation of colorectal cancer cells to elucidate whether ZG16p is involved in the anti-cancer mechanism in the intestinal epithelia. We found that ZG16p inhibits the proliferation of human colorectal cancer cell lines, Caco-2, LS174T, HCT116 and HCT15, and carbohydrate-binding sites in ZG16p play an essential role in the inhibitory activity. Furthermore, ZG16p suppressed the growth of patient-derived colorectal tumor organoids representing similar histopathological structures of original tumors (Fujii et al. 2016) .
Results

ZG16p inhibits proliferation of human colorectal cancer cells
To determine the effect of ZG16p proteins on colorectal cancer cells, ZG16p was overexpressed in Caco-2 cells and two stable transfectants, A1 and A2, were obtained. RT-PCR confirmed the expression of ZG16p-Strep-tag in A1 and A2 but not in mock cells ( Figure 1A) .
The cell growth rate between Caco-2 mock cells and the transfectants was assessed by WST-8 assay. Induction of ZG16p decreased the proliferation rate of Caco-2 cells ( Figure 1B ). After culturing for 7 days, cell numbers of A1 and A2 were reduced by 31 and 57%, respectively, compared to that of mock cells ( Figure 1B) .
Since ZG16p is a secreted protein, we examined the effect of extracellular ZG16p on cell proliferation by addition of recombinant ZG16p. Four human colorectal cancer cell lines, Caco-2, LS174T, HCT116 and HCT15, were incubated with ZG16p, and cell proliferation was analyzed by WST-8 assay. In the time course analysis, Caco-2 cell growth inhibition with 70 μg/mL ZG16p was found to be 16, 60 and 75% for 24, 48 and 72 h-incubations, respectively (Figure 2A, left) . Furthermore, Caco-2 cell proliferation was suppressed in a dose-dependent manner, i.e. ZG16p treatment of Caco-2 cells for 72 h resulted in 49, 62 and 71% inhibition at 30, 50 and 70 μg/mL, respectively (Figure 2A , right). LS174T cell proliferation was inhibited by 19 and 60% when cultured with 70 μg/mL ZG16p for 48 and 72 h, respectively (Figure 2B, left) , and by inhibited 7, 12, 32 and 60% with 10, 30, 50 and 70 μg/mL ZG16p for 72 h, respectively (Figure 2B, right) . Treatment of HCT116 cells with 70 μg/mL ZG16p for 48 and 72 h caused 39 and 65% inhibition, respectively ( Figure 2C , left). HCT116 cell growth was inhibited by 5, 49 and 65% by adding 30, 50 and 70 μg/mL ZG16p, respectively ( Figure 2C , right). HCT15 cell growth was only suppressed by incubation with 70 μg/mL ZG16p for 72 h (−62%) ( Figure 2D ). Interestingly, time-lapse imaging for 72 h indicated that Caco-2 cells treated with ZG16p grew for an initial period of about 30 h, after which the cell morphology decreased Fig. 1 . ZG16p overexpressing Caco-2 cells show lower proliferation rates compared to Caco-2 mock cells. (A) pEXPR-IBA103 or pEXPR-IBA103-ZG16p vector was stably transfected into Caco-2 cells. Expression levels of ZG16p and ZG16p-Strep-tag in Caco-2 mock, A1, and A2 cells were detected by RT-PCR. GAPDH was used as loading control. (B) Caco-2 mock, A1 and A2 cells were cultured for 1, 3, 5 and 7 days (n = 4). Cell growth was assessed by WST-8 assay. Error bars represent SD (*P < 0.05; ***P < 0.001 compared with mock cells, and ### P < 0.001 compared with A1 cells).
in size (Supplementary Data 1, Figure 2E shows the microphotograph at 72 h). This revealed that it took time to express the cell growth inhibition effect after adding ZG16p. In addition to four colorectal cancer cell lines, ZG16p was tested for the ability to reduce the growth of patient-derived colorectal tumor organoids, CRC15, which was confirmed to retain its original tumor identity (Fujii et al. 2016) . WST-8 assay after incubation with 70 μg/ mL ZG16p showed clear reduction of cell proliferation (−34%), whereas ZG16p-M5 did not inhibit organoid growth ( Figure 2F ).
These results indicate that ZG16p inhibits proliferation of colorectal cancer cells. Caco-2 cells were used for the following experiments as being most sensitive to ZG16p treatment. (1, 5, 10, 30, 50 and 70 μg/mL) for 72 h (right) (n = 4). Cell proliferation was measured by WST-8 assay. Error bars represent SD (*P < 0.05; ***P < 0.001 compared with control (no treatment with ZG16p)). (E) Photomicrographs of Caco-2 cells incubated with or without 70 μg/mL ZG16p for 72 h. (F) The patient-derived colorectal tumor organoids were incubated with ZG16p or ZG16p-M5 (35 or 70 μg/mL) for 72 h. Cell proliferation was measured using WST-8 assay. Error bars represent SD (***P < 0.001). The data shown are representative of two or three independent experiments.
ZG16p reduces the ratio of S-phase cells
To elucidate whether ZG16p inhibits the Caco-2 cell cycle, S-phase cells were detected by Click-iT EdU (5-ethynil-2′-deoxyuridine) assay. After treatment with ZG16p for 72 h, cells were incubated with EdU for 2 h. The EdU-positive cell ratio was 45, 12 and 2.3% in Caco-2 cells treated with 0, 35 and 70 μg/mL ZG16p, respectively ( Figure 3A ), indicating that ZG16p decreases S-phase cells.
ZG16p does not induce G0-phase transition
A proliferation marker Ki67 was detected in Caco-2 cells treated with 0, 35 and 70 μg/mL ZG16p for 72 h. There was no difference in the number of Ki67-positive cells between the control and treated cells ( Figure 3B ), revealing that ZG16p does not induce G0-phase transition.
ZG16p changes the expression levels of cell cyclerelated genes
To explore the genes responsible for anti-proliferative activity of ZG16p, the cell cycle-related genes regulated by ZG16p were identified by PCR array. Among the 84 cell cycle-related genes, the expression of six genes (WEE1, CDK6, TP53, RAD1, CCND1 and ATR) were upregulated and that of three genes (STMN1, MCM4 and CDKN1A) were downregulated by 2-fold or more by incubating with 70 μg/mL ZG16p for 72 h ( Figure 3C and Table I ).
ZG16p does not induce apoptosis and senescence
Apoptotic cells were detected by Annexin V-FITC and propidium iodide (PI) after treatment with 0, 35 and 70 μg/mL ZG16p for 72 h in Caco-2 cells. Both control and treated cells were not stained, Fig. 3 . ZG16p reduces the ratio of S-phase cells whereas ZG16p does not induce G0-phase transition in Caco-2 cells. (A) S-phase cells in Caco-2 cells treated with 35 or 70 μg/mL ZG16p for 72 h was detected by the Click-it EdU assay. The EdU-positive cell ratio is shown in the graph below as mean ± SD of three independent experiments (***P < 0.001 compared with control (ZG16p 0 μg/mL)). (B) A proliferation marker Ki67 in Caco-2 cells was detected after a 72-h incubation with 35 or 70 μg/mL ZG16p. (C) The expression of cell cycle-related gene regulated by ZG16p was identified. After 72 h of incubation with or without 70 μg/mL ZG16p, total RNA was isolated from Caco-2 cells and PCR array analysis was performed (n = 3). Negative fold-regulation is calculated as the negative inverse of the fold-change (Table I ). All differences are statistically significant (P < 0.05).
whereas cells treated with 2.5 mM sodium butyrate were slightly stained by Annexin V-FITC ( Figure 4A ).
To test whether ZG16p induces cellular senescence, senescenceassociated (SA)-β-galactosidase activity was detected in Caco-2 cells incubated with 0, 35 and 70 μg/mL ZG16p for 72 h. To avoid falsepositive results caused by cell confluence, 6.3 × 10 3 cells were seeded for the control assay, whereas 2.5 × 10 4 cells were seeded for treatment. The result showed no difference in the number of senescent cells between the control and treated cells, while the number of stained cells increased in 50 μM H 2 O 2 treated cells ( Figure 4B ).
These results show that cell apoptosis and senescence are not induced by ZG16p.
Two ZG16p mutants lack the mannose-binding or heparin-binding activity
To determine whether carbohydrate-binding sites of ZG16p are involved in the inhibition of cell growth, two mutant ZG16p proteins, ZG16p-D151A and ZG16p-M5, were established. Asp151 of ZG16p is responsible for binding to mannose (Tateno et al. 2012 ; Table I . Cell cycle-related genes that is upregulated and downregulated by 2-fold or more by incubating with 70 μg/mL ZG16p for 72 h in Caco-2 cells.
Gene bank
Gene Functional gene grouping: 1, G1 phase and G1/S transition; 2, S phase and DNA replication; 3, M phase; 4, cell cycle checkpoint and cell cycle arrest; 5, regulation of the cell cycle; 6, negative regulation of the cell cycle. Figure 5A ). Mannose-binding activity of ZG16p and ZG16p-D151A was assessed by a solid-phase assay. Consistent with a previous report (Tateno et al. 2012) , the binding of ZG16p-D151A to the α-mannose-PAA (polyacrylamide) probe was abolished ( Figure 5B ). In competition assays, the binding of ZG16p to an α-mannose-PAA probe was inhibited by 200 mM D-mannose and methyl α-D-mannoside ( Figure 5B ).
To compare heparin-binding activity of ZG16p and its mutants, affinity chromatography of these proteins with the HiTrap Heparin column was performed. ZG16p proteins were applied to a heparin column, and then eluted with a linear gradient (0-1.0 M) of NaCl. ZG16p, ZG16p-D151A and ZG16p-M5 were eluted with 0.62, 0.70 and 0.49 M NaCl, respectively ( Figure 5C ). As expected, the binding of ZG16p-M5 to heparin decreased, revealing that the five mutated amino acids (Lys36, Arg37, Arg55, Arg57 and Arg79) are involved in heparin binding. In contrast, binding of ZG16p-D151A to heparin was enhanced, in agreement with a previous study that showed increased heparin-binding activity of GST-ZG16p-D151N (Kanagawa et al. 2014 ). These findings suggest that the negative charge of Asp151 could reduce the binding of ZG16p to heparin.
ZG16p mutants do not inhibit Caco-2 cell growth
Cell growth inhibitory activity of ZG16p mutants was determined by WST-8 assay. Caco-2 cell proliferation was not inhibited by incubation with 70 μg/mL ZG16p-D151A or ZG16p-M5 for 72 h ( Figure 5D ).
ZG16p binds to the Caco-2 cell surface
Since ZG16p mutants did not show anti-proliferative activity, we hypothesized that ZG16p inhibits Caco-2 cell growth after binding to Caco-2 cell surfaces via its carbohydrate-binding sites. To visualize the binding of ZG16p and its mutants to Caco-2 cells, immunofluorescent cell staining was performed. As shown in Figure 5E , ZG16p and ZG16p-D151A could bind to Caco-2 cells, whereas ZG16p-M5 failed to bind. This result suggests that Lys36, Arg37, Arg55, Arg57 and Arg79 are required to bind to the cell surface and that Asp151 plays a key role in suppressing Caco-2 cell growth.
Discussion
In this study, we elucidated that lectin ZG16p inhibits colorectal cancer cell proliferation. Caco-2 cells overexpressing ZG16p exhibited slower growth than mock cells ( Figure 1B) . Treatment with recombinant ZG16p induced cell growth suppression of four colorectal cancer cell lines, Caco-2, LS174T, HCT116 and HCT15 (Figure 2A-D) . In addition, a recent study showed that the growth of HT29 cells overexpressing ZG16p is also inhibited (Chen et al. 2016) . However, the sensitivity to ZG16p differed between the four cell lines. It may be correlated with the difference of genomic mutation status in these cells. According to the exome mutation profiles (Mouradov et al. 2014) , the overall prevalence of mutation was high, in the order of HCT15 > HCT116 > LS174T > Caco-2, consistent with the resistance to ZG16p. As another possibility, the difference of the expression levels of carbohydrate ligands for ZG16p, i.e. heparan sulfate chains or mannose-containing glycans, in individual cell lines might cause this differing sensitivity to ZG16p.
Moreover, we also performed the proliferation assay using patient-derived colorectal tumor organoids (Fujii et al. 2016) . 3D organoid culture, a new system developed by Sato et al. (2009) , allows Lgr5+ stem cells from the murine small intestine to form crypt-villus structures containing differentiated cells. Fujii et al. (2016) recently established the patient-derived 55 colorectal tumor organoid lines and reported that each line recapitulated histological and morphological characteristics of primary tumors. CRC15 (poorly differentiated adenocarcinoma) was used in this study (Fujii et al. 2016) . As shown in Figure 2F , the growth of colorectal tumor organoids was suppressed by ZG16p but not by ZG16p-M5. On the other hand, there are 54 other patient-derived organoids with divergent characteristics regarding gene mutation status and degree of differentiation. The relationship between the sensitivity to ZG16p and the characteristics of organoids should be examined by using various organoid lines to elucidate the mechanism by which ZG16p exerts anti-proliferative effect.
As Caco-2 cells were the most sensitive to ZG16p, we attempted to elucidate the mechanism underlying cell growth suppression by ZG16p using Caco-2 cells. As shown in Figure 4A and B, ZG16p did not induce cell apoptosis and senescence, suggesting that Caco-2 cell growth is inhibited by inducing cell cycle arrest. The number of Ki67-positive cells did not differ between the control and ZG16p treated cells ( Figure 3B ), indicating that ZG16p does not induce G0-phase transition. EdU incorporation assay showed the remarkable reduction of S-phase cell ratio in the cells via ZG16p ( Figure 3A ). Based on these findings, we performed PCR array analysis to elucidate the change of cell cycle-related gene expression by culturing with ZG16p. It revealed that the expression of WEE1, CDK6, TP53, RAD1, CCND1 and ATR was upregulated and that of STMN1, MCM4 and CDKN1A was downregulated ( Figure 3C and Table I ). While there is no mutation of WEE1, CDK6, RAD1, CCND1, ATR, STMN1, MCM4 and CDKN1A (Mouradov et al. 2014; Klijn et al. 2015) , TP53 is mutated in Caco-2 cells (c.610G > T, p.Glu204*) (Liu and Bodmer 2006; Ahmed et al. 2013; Mouradov et al. 2014) . p53 encoded by TP53 is activated by cellular stresses such as DNA damage and leads to DNA repair, cell cycle arrest, apoptosis, anti-angiogenesis and feedback regulation of p53 itself (Giono and Manfredi 2006) . Although the expression of TP53 was upregulated in ZG16p treated cells (Figure 3C ), the p53-dependent G1 checkpoint would not work in Caco-2 cells (Ahmed et al. 2013 ). Cyclin D1 encoded by CCND1 forms a complex with cyclin-dependent kinase 6 (CDK6) and promotes G1/S transition (Ekholm and Reed 2000) . p21 encoded by CDKN1A acts as a cell cycle inhibitor by binding to and inhibiting CDK4, 6/cyclin D and CDK2/cyclin E (Karimian et al. 2016) . Therefore, the upregulation of CDK6 and CCND1 and the downregulation of CDKN1A ( Figure 3C ) suggest that G1/S transition might be activated in Caco-2 cells treated with ZG16p. Stathmin 1 encoded by STMN1 binds to α/β-tubulin heterodimers and is involved in promotion of microtubule depolymerization and inhibition of its polymerization (Rubin and Atweh 2004) . Stathmin-deficient cells cannot complete mitosis because disassembly of the mitotic spindle by active stathmin is necessary to exit from mitosis (Rubin and Atweh 2004) .
Minichromosome maintenance 4 (MCM4) is a component of the MCM 2-7 complex and MCM 2-7 acts as DNA helicase during S phase (Boos et al. 2012 ). The 9-1-1 complex (Rad9-Hus1-Rad1) is necessary for the DNA damage response carried out via ataxiatelangiectasia mutated and Rad3-related (ATR) . WEE1 is activated during S and G2 phases and promotes Tyr15 phosphorylation of CDK, leading to inhibition of CDK activity (Sørensen and Syljuåsen 2012) . Therefore, the downregulation of (B) Binding of ZG16p and ZG16p-D151A to an α-mannose-PAA probe was compared by a solid-phase assay (n = 3). The α-mannose-PAA probe was immobilized onto the plate and was incubated with ZG16p or ZG16p-D151A. The bound ZG16p proteins were detected by HRP-conjugated anti-Strep-tagII antibody.
D-mannose and methyl α-D-mannoside (Man-α-OMe) were preincubated with ZG16p as competitors. Error bars represent SD (***P < 0.001 compared with ZG16p with no inhibitor). The data shown are representative of two independent experiments. (C) Affinity chromatography of ZG16p, ZG16p-D151A or ZG16p-M5 on heparin column was performed. ZG16p proteins were eluted with a linear gradient (0-1.0 M) of NaCl at a flow rate of 1.0 mL/min. The eluate was monitored by absorbance at 280 nm. (D) Caco-2 cells were incubated with 70 μg/mL ZG16p, ZG16p-D151A, or ZG16p-M5 for 72 h (n = 4). Error bars represent SD (**P < 0.01; ***P < 0.001). The data shown are representative of two independent experiments. (E) The binding of ZG16p, ZG16p-D151A or ZG16p-M5 to Caco-2 cells was determined by immunofluorescent cell staining. Cells were grown on coverslips for 3 days prior to experimental treatment. Fixed cells were treated with 20 μg/ mL ZG16p proteins for 4 h. Bound ZG16p was detected with anti-Strep-tagII antibody. Green spots indicate bound ZG16p.
STMN1 and MCM4 and the upregulation of WEE1, RAD1 and ATR ( Figure 3C ) would represent cell cycle arrest during S or G2/M phase by ZG16p treatment in Caco-2 cells.
ZG16p is a unique lectin that has dual specificity for mannose and heparin/heparan sulfate. Two ZG16p mutants, ZG16p-D151A lacking mannose-binding activity and ZG16p-M5 (K36A, R37A, R53A, R55A and R79A) lacking heparin-binding activity, did not inhibit Caco-2 cell growth ( Figure 5D ). On the other hand, while ZG16p-D151A maintained its binding to the cell surface, ZG16p-M5 could not bind ( Figure 5E ). Taken together, these results demonstrate that ZG16p interacts with the Caco-2 cell surface via its heparin-binding site and that Asp151 is a key residue in the inhibition of Caco-2 cell proliferation. Like many growth factors including FGF (Spivak-Kroizman et al. 1994; Turner and Grose 2010) , hepatocyte growth factor (Rubin et al. 2001) , bone morphogenetic protein-7 (Irie et al. 2003) and Noggin (Paine-Saunders et al. 2002) , ZG16p probably interacts with heparan sulfate proteoglycans present on the cell surface via its basic amino acid residues and might utilize them as a scaffold exhibiting the anti-proliferative activity. Other receptors might also associate with Asp151 in ZG16p, and this interaction could induce signaling involving cell growth inhibition ( Figure 6 ). Whereas ZG16p does not bind to high-mannose Nglycans, ZG16p strongly binds to Ser/Thr-linked O-mannose (Kanagawa et al. 2014 ). However, whether or not O-mannosylation exists on apical membranes of intestinal epithelial cells (IECs) and Caco-2 cells has not been examined so far. Therefore, identification of the cell surface ligand of ZG16p is necessary to understand the signaling pathway that modulates colorectal cancer cell growth.
In this study, we investigated the anti-proliferative activity of ZG16p in colorectal cancer. Meanwhile, the function of ZG16p in normal IECs remains unclear. Recently, the downregulation of ZG16p expression was observed in organoids derived from patients with ulcerative colitis (Dotti et al. 2016) , suggesting that ZG16p plays a role in maintaining the homeostasis of IECs. In addition, the low expression of ZG16p in stem cells was suggested (Chen et al. 2016) . We then investigated the expression of ZG16p in various cell types in intestinal tissue using previously reported gene expression analyses. It is elucidated that ZG16p expression is higher in Paneth cells (GEO: GSE25109) (Sato et al. 2011) , and deep crypt secretory (DCS) cells (GEO: GSE63256) (Sasaki et al. 2016 ) than in stem cells.
Paneth cells and DCS cells support the maintenance of Lgr5-positive stem cells in the small intestine and colon, respectively (Sato et al. 2011; Sasaki et al. 2016) . These findings suggest the possibility that ZG16p regulates the stem cells.
In conclusion, we found that ZG16p suppresses the proliferation of colorectal cancer cell lines and the patient-derived colorectal tumor organoids through its carbohydrate-binding site. Further study is required to elucidate the mechanism of its growth inhibitory activity.
Materials and methods
Cell culture
Human colorectal cancer cell lines, Caco-2 and HCT116, were purchased from Cell bank (RIKEN, Ibaraki, Japan), and LS174T and HCT15 were obtained from Professor Tatsuro Irimura of The University of Tokyo. Caco-2 cells were grown in DMEM (high glucose, 3.5-4.5 g/L) supplemented with 20% heat-inactivated FBS and 1% nonessential amino acids. Other cells were grown in DMEM/ Ham's F12 supplemented with 10% FBS. Cells were incubated in an atmosphere of 5% CO 2 at 37°C.
Construction of the expression vector
For mammalian expression, the full-length human ZG16p gene (1-167 amino acids) was inserted into pEXPR-IBA103 (IBA, Goettingen, Germany) using the Eco31I site. For production of Strep-tagII-ZG16p, the human ZG16p gene (19-167 amino acids) was inserted into pASK-IBA5plus (IBA) using the EcoRI and BamHI sites. To prepare pASK-IBA5plus-ZG16p-M5, five amino acids (Lys36, Arg37, Arg53, Arg55 and Arg79) were substituted with Ala using the following primers: for K36A and R37A, 5′-GAGCGGCATTCTCTCATTCT GGCAACCAG-3′ and 5′-CACCACCACTTCCATACTCTCCACT ATAGG-3′; for R53A and R55A, 5′-GCGGTCGCAGTCAACAC ATACTACATCG-3′ and 5′-GAGGGCGGTGATGGGGCCGTCC AACTG-3′; for R79A, 5′-CAACGGAGACCTGGAGGAGATC TTTCTG-3′ and 5′-GCACCACCCACATAGTCGCTCCACACC TTG-3′. pASK-IBA5plus-ZG16p-D151A was constructed using the primer sets (5′-GCTGCCATTGGCCTGCACTGGGATGTTTAC-3′ and 5′-GATGAGAGAACCAGACCGGCCACTGATG-3′). The nucleotide sequence was confirmed using 3130 Genetic Analyzer (Applied Biosystems).
Establishment of stable cell lines
The expression plasmid pEXPR-IBA103-ZG16p was transfected into Caco-2 cells using Lipofectamine LTX reagents (Invitrogen) according to the manufacturer's instructions. For stable expression, cells were cultured in selective medium containing the antibiotic G418. Two single colonies were selected and named as A1 and A2. To establish mock cells, pEXPR-IBA103 was transfected into Caco-2 cells using Lipofectamine 3000 (Invitrogen) and cells were cultured in selective medium.
RT-PCR
Total cellular RNA was isolated using the illustra RNAspin Mini RNA Isolation Kit (GE Healthcare, Buckinghamshire, England) according to the manufacturer's instructions. cDNA was synthesized using the ReverTra Ace (TOYOBO, Osaka, Japan) and amplified using the KOD-Plus-Neo (TOYOBO) and the following primers: ZG16p, 5′-ATGTTGACAGTCGCTCTCCTAGCCCTTCTC-3′ and 
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5′-GTAAACATCCCAGTGCAGGCCAATGGCATC-3′;
ZG16p-Strep-tag, 5′-ATGTTGACAGTCGCTCTCCTAGCCCTTCTC-3′ and 5′-ACCTCCGGAACCTCCACCTTTCTCGAACTG-3′; GAPDH, 5′-TGAAGGTCGGAGTCAACGGATTTGGT-3′ and 5′-CATGT GGGCCATGAGGTCCACCAC-3′. PCR was performed with a 2-min heat activation of the enzyme at 94°C, followed by 25 (for GAPDH) or 30 (for ZG16p and ZG16p-Strep-tag) cycles at 98°C for 10 s and 68°C for 30 s. PCR products were separated by electrophoresis on 1.5% agarose gels.
Expression and purification of recombinant ZG16p
pASK-IBA5plus-ZG16p, pASK-IBA5plus-ZG16p-D151A and pASK-IBA5plus-ZG16p-M5 were transformed into Escherichia coli DH5α (Takara, Shiga, Japan) and the cells were grown in LB medium at 37°C. After induction with 200 μg/L anhydrotetracycline (IBA), the cells were grown for 4 h at 30°C. The harvested cells were resuspended in binding buffer (100 mM Tris-HCl (pH 8.0), 150 mM NaCl) and subjected to sonication. After centrifugation, the chaperon proteins were removed by incubating with 2 mM ATP, 10 mM MgSO 4 and 150 mM KCl for 10 min at 37°C. After centrifugation, the supernatants were applied to a StrepTrap HP column (GE Healthcare) equilibrated with binding buffer. After washing the column with binding buffer, the proteins were eluted with binding buffer containing 2.5 mM desthiobiotin. The purified proteins, Strep-tagII-ZG16p and its mutants, were replaced with PBS (10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , 137 mM NaCl and 2.7 mM KCl, pH 7.4). Protein concentration was estimated by using the Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA). The samples were analyzed on 15% SDS-PAGE and stained with Coomassie Brilliant Blue.
Cell proliferation assay
Caco-2 mock, A1 and A2 cells (5.0 × 10 3 cells/well) were seeded in 48-well plates and cultured in the serum-free medium ASF104 (Ajinomoto, Tokyo, Japan). After 1, 3, 5 and 7 days, WST-8 (Dojindo, Kumamoto, Japan) was added to each well. The plate was incubated for 2 h in an atmosphere of 5% CO 2 at 37°C, and absorbance at 450 nm was measured using Cytation3 imaging reader (BioTek, Winooski, VT). Caco-2 (1.0 × 10 4 cells/well), LS174T, HCT15 and HCT116
(5.0 × 10 3 cells/well) cells were cultured in 48-well plates for 24 h.
After washing with ASF104 supplemented with penicillin and streptomycin, the cells in ASF104 were treated with Strep-tagII-ZG16p at different concentrations (1, 5, 10, 30, 50 and 70 μg/mL) for 72 h; or treated with 70 μg/mL Strep-tagII-ZG16p for 24, 48 and 72 h. For growth assay of ZG16p mutants, Caco-2 cells were treated with 70 μg/mL Strep-tagII-ZG16p, Strep-tagII-ZG16p-D151A or StreptagII-ZG16p-M5 for 72 h. After treatment with ZG16p, WST-8 was added to each well and cells were incubated for 2 h. The number of cells was assessed by measuring absorbance at 450 nm.
Human colorectal tumor organoid culture
The patient-derived colorectal tumor organoid used in this study was previously established and characterized with slight modifications (Fujii et al. 2016) . Human colorectal tumor organoids, CRC15, were cultured as described previously (Fujii et al. 2016) . In brief, organoids were grown in drops of Matrigel, and the medium was refreshed every 2-5 days. The culture medium contained advanced DMEM/F12 (Thermo Fisher) with 1% penicillin/streptomycin (Thermo Fisher), 1% HEPES buffer (Thermo Fisher), 1%
Glutamax (Thermo Fisher), 1 × B27 (Thermo Fisher), 10 nM gastrin I (SIGMA), 1 mM N-acetylcysteine (Wako, Osaka, Japan) with three niche factors, ENA; 50 ng/ml murine EGF (Thermo Fisher), 10% Noggin condition medium (van de Wetering et al. 2015) , and 500 nM A83-01 (Tocris, Abington, UK). Organoids were cultured in an atmosphere of 5% CO 2 at 37°C and split through mechanical force (pipetting) and/or TrypLE Express treatment (Thermo Fisher 
Detention of Ki67-positive cells
A proliferation marker Ki67 in Caco-2 cells was detected. Caco-2 cells (2.0 × 10 4 cells/well) were grown on poly-L-lysine coated cover glass for 24 h. After 72-h incubation with 35 or 70 μg/mL Strep-tagIIZG16p in ASF104, the cells were washed with PBS and fixed with 4% PFA for 30 min at room temperature. After washing with PBS, the cells were permeabilized with 0.5% Triton X-100 for 20 min. Following washing with PBS, the cells were blocked with 0.4% gelatin from cold water fish skin (Sigma-Aldrich, St. Louis, MO) for 30 min. Ki67 expression was detected by rabbit anti-Ki67 antibody (Abcam, Cambridge, UK) diluted in blocking solution (1:500) and Alexa Fluor 488 goat anti-rabbit IgG antibody (Invitrogen) diluted in blocking solution (1:1000). The nuclei were counterstained with DAPI. After washing with PBS, the cells were mounted and were visualized by a confocal laser scanning microscope (LSM 700).
PCR array
Caco-2 cells (8.0 × 10 5 cells/dish) were cultured in 10 cm dishes for 24 h. After 72-h incubation with 70 μg/mL Strep-tagII-ZG16p in ASF104, total RNA was isolated using the illustra RNAspin Mini Isolation Kit. PCR assay was performed using the Human Cell Cycle RT 2 Profiler PCR Array (SABiosciences/Qiagen, Hilden, Germany) following the manufacturer's instructions. Reverse transcription was performed from 1 μg total RNA using the RT 2 First
Strand Kit (SABiosciences). Real-time PCR was performed (StepOnePlus, Applied Biosystems) with a 10-min heat activation of the enzyme at 95°C, followed by 40 cycles at 95°C for 15 s and 60°C for 60 s. The web-based software package, RT 2 Profiler PCR Array Data Analysis version 3.5, automatically performed all ΔΔCt based fold-change calculations from the uploaded raw threshold cycle data. For the normalization, the average of five housekeeping genes, ACTB, B2M, GAPDH, HPRT1 and RPLP0, was used. The data from the PCR array have been deposited in the GEO database under accession number GSE84321.
Annexin V apoptosis assay
Inversion and perforation of cell membranes in apoptotic cells were detected by Annexin V-FITC and PI using the RayBio Annexin V-FITC Apoptosis Detection Kit (RayBiotech, Inc., Norcross, GA). Caco-2 cells (2.5 × 10 4 cells/well) were grown for 24 h. After washing with ASF104, 35 or 70 μg/mL Strep-tagII-ZG16p or 2.5 mM sodium butyrate was added to the cells in ASF104. After 72-h incubation, the cells were washed with PBS and stained with Annexin V-FITC and PI for 15 min in the dark. After washing with PBS, cells were fixed with 4% PFA for 15 min. Following washing with PBS, DNA was stained with DAPI for 30 min. After mounting, stained cells were visualized by a confocal laser scanning microscope (LSM 700).
SA-β-galactosidase assay
Cellular senescence was assessed by β-galactosidase activity using the Cellular Senescence Kit (OZ Biosciences, San Diego, CA). Caco-2 cells (6.3 × 10 3 and 2.5 × 10 4 cells/well) were grown for 24 h.
After washing with ASF104, 35 or 70 μg/mL Strep-tagII-ZG16p, or 50 μM H 2 O 2 was added to the cells in ASF104. After 72-h incubation, the cells were then processed following the manufacturer's instruction. Stained cells were incubated with 1× staining solution of SA X-Gal for 18 h and were visualized by an inverted microscope (CKX41, Olympus, Tokyo, Japan).
Mannose binding assay
5 μg/mL α-D-mannose-PAA (GlycoTech, Gaithersburg, MD) was immobilized on an ELISA plate (IWAKI, Shizuoka, Japan). Following washing with PBS, the wells were blocked with PBS containing 3% BSA (Wako) for 1 h at room temperature. The coated wells were then incubated with 10 μg/mL Strep-tagII-ZG16p or Strep-tagII-ZG16p-D151A in PBS containing 1.5% BSA for 4 h. For the competitive inhibition assay, Strep-tagII-ZG16p was preincubated with 200 mM D-mannose or methyl α-D-mannoside for 15 min. After washing with PBS, the wells were incubated with HRP-conjugated anti-Strep-tagII antibody (IBA) diluted in PBS containing 1.5% BSA (1:1000) for 1 h. After washing with PBS, 100 mM citrate-phosphate buffer (pH 5.0) containing 0.04% orthophenylenediamine and 0.01% H 2 O 2 was added. The reaction was stopped with 4 M H 2 SO 4 , and absorbance at 490 nm was measured.
Heparin binding assay
A HiTrap Heparin HP column (GE Healthcare) connected to an ÄKTApurifier (GE Healthcare) was equilibrated with 10 mM TrisHCl (pH 7.0) and 2 mM CaCl 2 . Strep-tagII-ZG16p, Strep-tagIIZG16p-D151A or Strep-tagII-ZG16p-M5 was applied to the column. The column was washed and then eluted at a flow rate of 1.0 mL/min with a linear gradient (0-1.0 M) of NaCl in 10 mM Tris-HCl (pH 7.0) and 2 mM CaCl 2 , and absorbance at 280 nm was measured.
Binding of ZG16p to Caco-2 cells 
Statistical analysis
The data presented are the mean ± SD. Statistical analysis was performed using BellCurve for Excel (Social Survey Research Information Co., Ltd., Tokyo, Japan). Multiple group comparison was performed by Tukey-Kramer or Dunnett's test. For time course analysis, the results were analyzed using two-way analysis of variance followed by Tukey test. A P value < 0.05 was considered as statistically significant.
